Skip to main content

Table 2 Best corrected visual acuity between the groups and in general

From: Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study

Drug

Time

n

 

p

   

Mean ± SD

Median (Q1–Q3)

 

Aflibercept

 

Baseline

33

0.81 ± 0.27

0.70 (0.57–1.00)

 < 0.001

 

Final

33

0.17 ± 0.06

0.18 (0.10–0.18)

Z = 5.020; r = 0.87

Bevacizumab

 

Baseline

32

0.89 ± 0.28

1.00 (0.63–1.00)

 < 0.001

 

Final

32

0.41 ± 0.20

0.54 (0.18–0.60)

Z = 4.688; r = 0.82

Ranibizumab

 

Baseline

33

1.00 ± 0.29

1.00 (0.70–1.30)

 < 0.001

 

Final

33

0.43 ± 0.19

0.54 (0.24–0.60)

Z = 4.946; r = 0.86

Ziv-aflibercept

 

Baseiline

33

0.99 ± 0.31

1.00 (0.70–1.30)

 < 0.001

 

Final

33

0.41 ± 0.22

0.40 (0.18–0.60)

Z = 4.806; r = 0.84

  1. Note: p → Wilcoxon’s test; r → effect size
Back to article page

International Journal of Retina and Vitreous

ISSN: 2056-9920

Contact us